X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs BIOCON LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA BIOCON LTD SUN PHARMA/
BIOCON LTD
 
P/E (TTM) x 26.0 79.3 32.7% View Chart
P/BV x 3.8 7.5 50.8% View Chart
Dividend Yield % 0.6 0.2 364.7%  

Financials

 SUN PHARMA   BIOCON LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
BIOCON LTD
Mar-17
SUN PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs8421,162 72.5%   
Low Rs572483 118.6%   
Sales per share (Unadj.) Rs131.6194.6 67.7%  
Earnings per share (Unadj.) Rs32.734.4 95.1%  
Cash flow per share (Unadj.) Rs38.048.3 78.7%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.50.1 406.9%  
Book value per share (Unadj.) Rs152.7241.9 63.1%  
Shares outstanding (eoy) m2,399.26200.00 1,199.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.44.2 127.2%   
Avg P/E ratio x21.623.9 90.5%  
P/CF ratio (eoy) x18.617.0 109.3%  
Price / Book Value ratio x4.63.4 136.2%  
Dividend payout %10.72.9 368.2%   
Avg Mkt Cap Rs m1,696,877164,440 1,031.9%   
No. of employees `00017.59.2 189.7%   
Total wages/salary Rs m49,0237,470 656.3%   
Avg. sales/employee Rs Th18,028.34,213.9 427.8%   
Avg. wages/employee Rs Th2,798.8809.0 346.0%   
Avg. net profit/employee Rs Th4,479.5745.2 601.1%   
INCOME DATA
Net Sales Rs m315,78438,911 811.6%  
Other income Rs m6,2321,571 396.7%   
Total revenues Rs m322,01640,482 795.5%   
Gross profit Rs m100,8939,795 1,030.0%  
Depreciation Rs m12,6482,772 456.3%   
Interest Rs m3,998260 1,537.7%   
Profit before tax Rs m90,4798,334 1,085.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1161,616 749.7%   
Profit after tax Rs m78,4626,881 1,140.3%  
Gross profit margin %31.925.2 126.9%  
Effective tax rate %13.419.4 69.1%   
Net profit margin %24.817.7 140.5%  
BALANCE SHEET DATA
Current assets Rs m329,53740,477 814.1%   
Current liabilities Rs m178,87016,783 1,065.8%   
Net working cap to sales %47.760.9 78.4%  
Current ratio x1.82.4 76.4%  
Inventory Days Days7960 132.5%  
Debtors Days Days8383 100.5%  
Net fixed assets Rs m204,76645,073 454.3%   
Share capital Rs m2,3991,000 239.9%   
"Free" reserves Rs m363,99747,377 768.3%   
Net worth Rs m366,39748,377 757.4%   
Long term debt Rs m14,36121,082 68.1%   
Total assets Rs m614,10293,942 653.7%  
Interest coverage x23.633.1 71.5%   
Debt to equity ratio x00.4 9.0%  
Sales to assets ratio x0.50.4 124.1%   
Return on assets %13.47.6 176.6%  
Return on equity %21.414.2 150.6%  
Return on capital %24.812.6 197.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11812,988 339.7%   
Fx outflow Rs m24,4847,899 310.0%   
Net fx Rs m19,6345,089 385.8%   
CASH FLOW
From Operations Rs m70,8226,400 1,106.6%  
From Investments Rs m-42,216-4,985 846.9%  
From Financial Activity Rs m-22,854-1,775 1,287.5%  
Net Cashflow Rs m6,107-473 -1,291.1%  

Share Holding

Indian Promoters % 63.7 40.4 157.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.1 8.4 61.1%  
FIIs % 23.0 10.7 215.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 19.9 41.7%  
Shareholders   133,026 109,995 120.9%  
Pledged promoter(s) holding % 0.5 0.0 1,325.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green. Sectoral indices are trading on a mixed note, with stocks in the IT sector.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 22, 2018 03:33 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ELDER PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS